Deciphering the anticancer potential of thymoquinone: in-depth exploration of the potent flavonoid from Nigella sativa
Molecular Biology Reports · 2025
DOI: 10.1007/s11033-025-10375-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Bunty Sharma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Graphic Era (Deemed to Be University), Dehradun, Uttarakhand, India. Hauptthemen laut MEDLINE: Benzoquinones, Nigella sativa, Neoplasms, Flavonoids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 89 Literaturangaben.
Abstract (Originalsprache)
Since its first written description around 3000 BC until the present day, cancer has stood as a leading global cause of death, claiming the lives of 1 in 6 individuals. Due to its widespread impact and lethality, it remains one of the most explored yet most challenging disease for the global scientific community. Throughout history, various plant extracts have been used in treating numerous diseases, including cancer. These natural extracts are regaining attention due to their therapeutic benefits and lesser side effects. Thymoquinone, chemically 2-isopropyl-5-methylbenzo-1,4-quinone, constitutes the primary bioactive component of the plant Nigella sativa. Extensive research across in vivo, in vitro models, and clinical trials has revealed Thymoquinone's noteworthy therapeutic potential against cancer. Thymoquinone has shown promising anti-cancer activity in various cancers including breast cancer, lung cancer, prostate cancer, colorectal cancer, cervical cancer, pancreatic cancer, gastric cancer and blood cancers. However, there are challenges such as limited clinical trials, low bioavailability, and the need for more research to understand its long-term safety and effectiveness. This article provides a comprehensive and thorough review of thymoquinone, covering its effectiveness across various malignancies, the molecular signalling pathways it influences, and its role in triggering apoptosis and inhibiting inflammation, angiogenesis, and metastasis. Additionally, the review includes a thorough examination of thymoquinone's pharmacokinetics and safety, making it the first of its kind in its comprehensiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Graphic Era (Deemed to Be University), Dehradun, Uttarakhand, India.
- Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bhatinda, 151001, India.
- Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, 45142, Jazan, Saudi Arabia.
- Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, 1102 2801, Lebanon.
- University Centre for Research & Development, University Institute of Pharmaceutical Sciences, Chandigarh University, Gharuan, Mohali, Punjab, 140413, India.
- Department of Bio-Sciences and Technology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala, 133207, India.
Zitieren
APA
Sharma, B., Shekhar, H., Sahu, A., Haque, S., Kaur, D., Tuli, H. S., & Sharma, U. (2025). Deciphering the anticancer potential of thymoquinone: in-depth exploration of the potent flavonoid from Nigella sativa. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10375-9
Vancouver
Sharma B, Shekhar H, Sahu A, Haque S, Kaur D, Tuli HS, et al. Deciphering the anticancer potential of thymoquinone: in-depth exploration of the potent flavonoid from Nigella sativa. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-10375-9
BibTeX
@article{Sharma2025,
author = {Sharma, Bunty and Shekhar, Himanshu and Sahu, Anidrisha and Haque, Shafiul and Kaur, Damandeep and Tuli, Hardeep Singh and Sharma, Ujjawal},
title = {Deciphering the anticancer potential of thymoquinone: in-depth exploration of the potent flavonoid from Nigella sativa},
journal = {Molecular Biology Reports},
year = {2025},
doi = {10.1007/s11033-025-10375-9}
}
EUVIMED